Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
NCT05651672Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib in gastrointestinal cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Dec 2022; status: recruiting.
02
Drugs
pemigatinib
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT05651672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651672.